HIV
General Medicine · Topic 6
Source: NMC CBME Curriculum 2024 · Volume II · General Medicine · Topic 6 · combined PDF page 291
Practice questions
- Under the 2026 Belgian guidance, a pregnant woman living with HIV has a viral load of 35 copies/mL at week 36. Which delivery plan is recommended?
- At 36 weeks of pregnancy, a woman living with HIV has a viral load of 420 copies/mL. According to the 2026 Belgian guidance, which intrapartum measure is indicated?
- A pregnant woman living with HIV has a viral load of 1,250 copies/mL at week 36. Which plan matches the 2026 Belgian guidance?
- A woman’s HIV viral load is ≤50 copies/mL before conception and remains ≤50 copies/mL throughout pregnancy. Under the cited Belgian guidance, what is indicated for the newborn specifically as antiretroviral prophylaxis?
- A woman living with HIV has maintained full viral suppression from conception to delivery and asks about breastfeeding. Which statement best reflects the 2026 Belgian guidance?
- In the cited Belgian guidance, a woman living with HIV chooses exclusive breastfeeding. Which follow-up approach is specified to help minimize transmission risk?
- At week 36, a pregnant woman’s viral load is 700 copies/mL. She asks whether a scheduled caesarean section is compulsory. Which response best reflects the cited Belgian guidance?
- A randomized-trial meta-analysis of doravirine/islatravir reported an islatravir-dose-related immunological signal. Which dose was associated with CD4 and lymphocyte declines?
- In the 2026 meta-analysis, what was the reported immunological characterization of the 0.25-mg islatravir dose in doravirine/islatravir?
- Across the randomized trials included in a 2026 meta-analysis, how did doravirine/islatravir compare with active controls for week-48 viral suppression?
- The pooled comparison of doravirine/islatravir with active comparators reported a relative risk of virological failure of 0.55 (95% CI 0.33–0.92). Which interpretation is most appropriate?
- In the 2026 review, doravirine/islatravir was compared with bictegravir/emtricitabine/tenofovir alafenamide for change in weight. What was the reported finding?
- In an included study of people living with HIV, HPV16 seroconversion was compared by CD4 count. Which result was reported?
- What pooled HPV16 seroconversion rate did the 2026 systematic review and meta-analysis report for people living with HIV?
- Regarding safety, what did the 2026 systematic review report about serious adverse events related to prophylactic HPV vaccines in people living with HIV?
- A study of the nonavalent HPV vaccine in virologically suppressed women living with HIV compared two doses with three doses. Which conclusion did the 2026 review report?
- In a meta-analysis of observational studies of mpox, HIV coinfection was associated with what pooled relative risk of hospitalization?
- A systematic review of mpox outcomes reported a pooled mortality relative risk of 4.54 (95% CI 2.11–9.77) for patients with HIV coinfection. What does this estimate indicate?
- Which clinical feature was reported as more common among mpox patients with HIV coinfection in the systematic review?
- The mpox meta-analysis suggested in exploratory subgroup analyses that poor HIV viral suppression may drive adverse outcomes. How should this finding be interpreted?
- A patient living with HIV has a hematologic malignancy for which stem-cell transplantation is indicated. According to the 2026 review and practice guideline, how should HIV status affect transplant eligibility?
- For a person living with HIV undergoing stem-cell transplantation, what approach to antiretroviral therapy is supported by the cited review?
- During planning for allogeneic stem-cell transplantation in a person living with HIV, a suitable donor homozygous for CCR5-Δ32 is available. What does the cited guidance say about this donor feature?
- A symptomatic man has non-gonococcal urethritis. According to the 2026 BASHH guideline, which organisms are identified as the most common causes?
- A symptomatic man has urethral discharge, and NGU is suspected. Which diagnostic approach is described in the 2026 BASHH guideline?